Best Peptides TodayPeptide news, regulatory status and trial analysis.https://bestpeptidestoday.com/en-usEdition 1: HHS's Peptide Policy, Retatrutide's Phase 3 Data and an FDA Warning Letterhttps://bestpeptidestoday.com/newsletter/1-peptide-week-in-review/https://bestpeptidestoday.com/newsletter/1-peptide-week-in-review/Best Peptides Today, edition 1: HHS's interim peptide compounding policy, retatrutide's phase 3 results and an FDA warning letter on compounded GLP-1s.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamCagriSema Awaits an FDA Decision. Here Is What the Trials Show, and What Only Novo Has Saidhttps://bestpeptidestoday.com/news/cagrisema-awaits-fda-decision-trial-results/https://bestpeptidestoday.com/news/cagrisema-awaits-fda-decision-trial-results/Novo expects an FDA decision on CagriSema in Q4 2026. What is published, what only Novo has reported, and why the tirzepatide comparison is not simple.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamFDA Warning Letter Says Empower Pharmacy's Compounded Semaglutide and Tirzepatide Appear to Be Copieshttps://bestpeptidestoday.com/regulatory/fda-warning-letter-empower-pharmacy-compounded-semaglutide-tirzepatide/https://bestpeptidestoday.com/regulatory/fda-warning-letter-empower-pharmacy-compounded-semaglutide-tirzepatide/FDA says Empower's compounded semaglutide and tirzepatide with added ingredients appear to be copies of approved drugs. It is FDA's position, not a ruling.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamLarge Study Links GLP-1 Drugs to Lower Heart and Kidney Risk, and Higher Risk of Some Other Conditionshttps://bestpeptidestoday.com/analysis/glp-1-drugs-type-2-diabetes-multisystem-study-associations/https://bestpeptidestoday.com/analysis/glp-1-drugs-type-2-diabetes-multisystem-study-associations/A study of about 71,000 adults with type 2 diabetes found 65 lower-risk and 53 higher-risk associations with GLP-1 drugs. It shows association, not cause.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamHHS Issues Interim Policy on Compounding Six Peptides, Including BPC-157 and TB-500https://bestpeptidestoday.com/regulatory/hhs-interim-policy-peptide-compounding-503a/https://bestpeptidestoday.com/regulatory/hhs-interim-policy-peptide-compounding-503a/HHS says it does not intend to act against some 503A compounding of six peptides, under conditions. It is open for comment and is not FDA approval.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamRetatrutide's Phase 3 Results Are Now in NEJM and The Lancet. The Drug Is Still Unapprovedhttps://bestpeptidestoday.com/news/retatrutide-phase-3-triumph-1-triumph-2-results/https://bestpeptidestoday.com/news/retatrutide-phase-3-triumph-1-triumph-2-results/TRIUMPH-1 and TRIUMPH-2 show large weight loss with investigational retatrutide. Why Lilly's figures and the journals' differ, and what is not yet known.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamAlabama and Mississippi Boards Warned on Peptides Before HHS's Interim Policy. How They Fit Is Unclearhttps://bestpeptidestoday.com/regulatory/state-board-peptide-notices-and-hhs-compounding-policy/https://bestpeptidestoday.com/regulatory/state-board-peptide-notices-and-hhs-compounding-policy/Alabama and Mississippi boards told licensees not to compound non-FDA-approved or research-grade peptides. Both predate HHS's policy; the fit is unclear.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamWhat FDA's Warning Letters Say About 'Research Use Only' Peptideshttps://bestpeptidestoday.com/analysis/what-fda-warning-letters-say-about-research-use-only-peptides/https://bestpeptidestoday.com/analysis/what-fda-warning-letters-say-about-research-use-only-peptides/FDA warning letters to three peptide sellers say 'research use only' labels did not change its conclusion. What FDA cited and what a letter does not prove.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial TeamWhat the BPC-157 Research Actually Shows: Animal Studies, a Few Small Human Reportshttps://bestpeptidestoday.com/analysis/what-the-bpc-157-research-actually-shows/https://bestpeptidestoday.com/analysis/what-the-bpc-157-research-actually-shows/BPC-157 is in the news after HHS's interim policy. Here is what the research covers in animals and in people, and what FDA says is missing.Sat, 31 Oct 2026 00:00:00 GMTBest Peptides Today Editorial Team